Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine

Pulmatrix, Inc.

IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.
Phase 1 data showed PK similar to IV DHE with fewer side effects.
Phase 2 protocol investigates safety and preliminary efficacy in migraine patients.
Approximately 40 million U.S. patients with acute migraine need additional options.
PUR3100 uses proprietary iSPERSE dry powder delivery technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.